Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials
Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in patients with CHE for up to 52 weeks.
Authors
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- M.N. Crépy (ORCID: https://orcid.org/0000-0002-9824-1034)
- Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
- Luca Stingeni (ORCID: https://orcid.org/0000-0001-7919-8141)
- E. Serra‐Baldrich (ORCID: https://orcid.org/0000-0001-7603-0300)
- Margitta Worm (ORCID: https://orcid.org/0000-0002-3449-1245)
- Ursula Plohberger (ORCID: https://orcid.org/0009-0005-7351-8825)
- Sibylle Schliemann
- Tove Agner (ORCID: https://orcid.org/0000-0002-7543-8299)
- Silvia Mariel Ferrucci (ORCID: https://orcid.org/0000-0002-6734-1366)
- Sonja Molin (ORCID: https://orcid.org/0000-0002-9383-034X)
- Marie L. A. Schuttelaar (ORCID: https://orcid.org/0000-0002-0766-4382)
- Marie Louise Oesterdal
- Cherry Lou Balita-Crisostomo
- Melinda Gooderham
- Richard B. Warren
Institutions
- University of Copenhagen (DK)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- George Washington University (US)
- Queen's University (CA)
- University of Perugia (IT)
- Manchester Academic Health Science Centre (GB)
- Hospital de Sant Pau (ES)
- Bispebjerg Hospital (DK)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Manchester University NHS Foundation Trust (GB)
- ENT and Allergy (US)
- Clinical Research Center for Hair and Skin Science (DE)
- Jena University Hospital (DE)
- Innovaderm (Canada) (CA)
- NIHR Manchester Biomedical Research Centre (GB)
- Leo Pharma (Denmark) (DK)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1016/j.jaad.2025.03.008
- Citations
- 18
- Primary Topic
- Contact Dermatitis and Allergies
- Type
- article
- Field-Weighted Citation Impact
- 36.09
Funders
- National Institute for Health and Care Research
- LEO Pharma
- Manchester Biomedical Research Centre